

Sara Sheikholeslami

5/16/2021



- **Date of birth:** 11st October 1985
- **Current Address:** Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences. Tehran–Iran.
- **Office Phone:** +98(21)22432500 (ext.234)
- **Permanent Address:** Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences. Tehran – Iran.
- **Email address:** sara.sheikholeslami@gmail.com
- **LinkedIn Account:** <https://www.linkedin.com/in/sara-sheikholeslami-a9151039/>
- **Scopus ID:** 55188686400
- **ORCID ID:** 0000-0002-6594-4251

EDUCATION

- **Ph.D. in Biomedicine**

Shahid Beheshti University of Medical Sciences, Tehran, Iran (2014-2020)

Ph.D. Thesis; The study of the association of Plasma Selenium levels in papillary thyroid carcinoma patients and the Effect of selenium on Methylation of *DAPK1*, *SLC5A8*, *.SOCS6*, *RSK4*, *NOL4* tumor Suppressing Genes in Thyroid Papillary Cancer cell line.

- **MSc. in Biochemistry**

Islamic Azad University, Science and Research Branch, Tehran, Iran (2008 – 2010)

MSc. Thesis; Evaluation of thyroxine and thyrotropin hormone levels and five germline mutations in RET proto-oncogene Exon 11 in Iranian Medullary Thyroid Carcinoma

- **BS. in Nutrition Science**

National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran (2003-2007)

EXPERIENCE

Researcher, Cellular and molecular research center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
From 2013 to now

Research Assistant, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
From 2008 to 2013

Quality Control Manager, Zarrineh Tam Co, Qazvin, Iran
From 2010 to 2015

SKILLS & ABILITIES

- DNA and RNA extraction, purification
- PCR techniques (RT-PCR, ARMS, Real-Time PCR)
- RFLP (restriction fragment length polymorphism)
- Electrophoresis techniques (Protein and DNA)
- Silver Staining Methods for Poly acrylamide gel (Protein and DNA)
- Bioinformatics analysis of DNA, RNA, and Protein sequences (Blast, Alignment)
- Methylation analysis (HRM, MSP)
- Primer design for mutation detection, expression, and methylation
- Writing proposal and scientific paper
- cell culture experience
- Drug treatment of cancer cells
- MTT assay

SOFTWARE SKILLS

Microsoft Office, EndNote

Statistical analysis software; SPSS, GraphPad prism

Primer Design Soft wares; Gene runner, Allele ID, Primer3

Bioinformatics analysis soft wares; REST software, GenEX, Progeny 7

JOURNAL PUBLICATION

1. Hedayati Mehdi, Zarif Yeganeh Marjan, **Sheikhol Eslam Sara**, Rezghi Barez Shekoufe, Hoghooghi Rad Laleh, Azizi Fereidoun. Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma. Journal of Thyroid Research. J Thyroid Res. 2011;264248. Epub 2011 Jun 13.
2. Asghari G, **Sheikholeslami S**, Mirmiran P, Chary A, Hedayati M, Shafiee A, Azizi F. Effect of pomegranate seed oil on serum TNF- α level in dyslipidemic patients. Int J Food Sci Nutr. 2012 May; 63(3):368-71.
3. Mahdi Rafiei, Marjan Zarif Yeganeh, **Sara Sheikhol Eslami**, Elnaz Gozalpour, Majid Ghaffarpour, Mehdi Hedayati. Apolipoprotein E Polymorphisms Status in Iranian Patients with Multiple Sclerosis. J Neurol Sci. 2012 Sep 15;320(1-2):22-5.
4. Maryam emadi, fahimeh ramezani tehrani, parichehre yaghmaei, **sara sheikholeslami**, Mehdi Hedayati, Serum adiponectin levels and its association with insulin resistance and obesity in women with poly cystic ovarian syndrome, Razi journal of medical sciences, 19 (101) oct-nov 2012
5. **Sheikholeslami Sara**, Zarif Yeganeh Marjan, Hoghooghi Rad Laleh, Ghadaksaz Golab Hoda, Hedayati Mehdi. Haplotype Frequency of G691S/S904S in the RET proto-oncogene in Patients with Medullary Thyroid Carcinoma. Iran J Public Health. 2014 Feb;43(2):235-40.
6. Lotfi J, Taghikhani M, Yeganeh M Z, **Sheikholeslami S**, Hedayati M. Single nucleotide polymorphism of rs1800247 in promoter region of osteocalcin gene in patients with medullary thyroid carcinoma. Journal of Isfahan Medical. 2014; 32(276).
7. Hosseini S, Hashemzadeh S, Estiar MA, Ebrahimzadeh R, Fakhree MB, Yousefi B, **Sheikholeslami Sara**, Modarresi MH, Sakhinia E. Expression Analysis of Aurora-C and Survivin, Two Testis-Specific Genes, in Patients with Colorectal Cancer. Clin Lab. 2015;61(5-6):475-80.

8. Zarif Yeganeh Marjan, **Sheikholeslami Sara**, Hedayati Mehdi. RET Proto Oncogene Mutation Detection and Medullary Thyroid Carcinoma Prevention. *Asian Pac J Cancer Prev.* 2015;16(6):2107-17.
9. Zarif Yeganeh Marjan, **Sheikholeslami Sara**, Dehbashi Behbahani Golnoush, Samaneh Farashi, Hedayati Mehdi. Skewed mutational spectrum of RET proto-oncogene Exon10 in Iranian patients with medullary thyroid carcinoma. *Tumour Biol.* 2015 Jul;36(7):5225-31.
10. Hedayati M, Zarif Yeganeh Marjan, **Sheikholeslami S**, Afsari F. Diversity of Mutations in the RET proto-oncogene and its Oncogenic Mechanism in Medullary Thyroid Cancer. *Crit Rev Clin Lab Sci.* 2015 Dec 18:1-35.
11. **Sheikholeslami S**, Zarif Yeganeh M, Razavi SA, Nasiri S and Hedayati M. A Decade Mutational Screening: Exon 16 of RET Proto-Oncogene Mutations in Medullary Thyroid Carcinoma. *Annals of Thyroid Research.* May 30, 2016.
12. Ehyaei S, Hedayati M, Zarif-Yeganeh M, **Sheikholeslami S**, Ahadi M, Amini SA. Relationship between Serum Calcitonin Levels and miRNA323 Expression in Medullary Thyroid Carcinoma Patients with or without RET Proto-oncogene Mutation. *Asian Pac J Cancer Prev.* 2017 Aug 27;18(8):2179-2184.
13. **Sheikholeslami S**, Ghanbarian A, Azizi F. The Impact of Physical Activity on Non-communicable Diseases: Findings from 20 Years of the Tehran Lipid and Glucose Study. *Int J Endocrinol Metab.* 2018 Oct 14;16(4 Suppl):e84740.
14. Hedayati M, Daneshpour MS, Zarkesh M, Zarif Yeganeh M, **Sheikholeslami S**, Faam B, Azizi F. Biochemical Assessment: Findings from 20 Years of the Tehran Lipid and Glucose Study. *Int J Endocrinol Metab.* 2018 Oct 16;16(4 Suppl):e84783
15. Karimi H, Nezhadali M, Hedayati M, Mahdavi M, **Sheikholeslami S**. The Impact of Adiponectin Gene Polymorphisms on the Insulin Resistance Index in Patients with Diabetes and Newly Diagnosed Type 2 Diabetes. *International Journal of Diabetes & Metabolism.* 2019 Sep. DOI: 10.1159/000502904
16. Fatemeh Razavi, **sara Sheikholeslami**, Marjan Zarif Yeganeh, Tahereh Najji, Mehdi Hedayati. Plasma Ceruloplasmin status in Medullary Thyroid Carcinoma. *Iranian journal of public health.* 2020 Jan;49(1):209-210.
17. Shabani N, **Sheikholeslami S**, Paryan M, Zarif Yeganeh M, Tavangar SM, Azizi F, Mohammadi-Yeganeh S, Hedayati M. An investigation on the expression of miRNAs including miR-144 and miR-34a in plasma samples of RET-positive and RET-negative medulla thyroid carcinoma patients. *J Cell Physiol.* 2020 Feb; 235(2):1366-1373. doi: 10.1002/jcp.29055. Epub 2019 Jul 11.

18. **Sheikholeslami S**, Shabani N, Shivaee S, Tavangar SM, Yeganeh M, Hedayati M, Loffi J, Gholami H. Overexpression of mir-129-1, miR-146b, mir-183, and mir-197 in Follicular Thyroid Carcinoma and Adenoma Tissues. *Mol Cell Probes*. 2020 Jun; 51:101536. doi: 10.1016/j.mcp.2020.101536. Epub 2020 Feb 18.
19. Fatemeh Razavi, **Sara Sheikholeslami**, Marjan Zarif Yeganeh, Tahereh Najji, Mehdi Hedayati. Ceruloplasmin Status in Medullary Thyroid Carcinoma. *Iran J Public Health*. 2020 Jan; 49(1):209-210.
20. Rahmani Samani M, Zarif yeganeh M, Mehrabi A, Emami Razavi AN, **Sheikholeslami S**, Hedayati M. Expression of miR-127, miR-154, and miR-183 in Medullary Thyroid Carcinoma Tumors. *Iranian journal of public health*. *Iran J Public Health*. 2021 Feb;50(2):391-396.
21. **Sara Sheikholeslami**, Fereidoun Azizi, Asghar Ghasemi, Abbas Alibakhshi, Hossein Parsa, Seyed Mohammad Tavangar, Setareh Shivaee, Marjan Zarif Yeganeh, Mehdi Hedayati, Ladan Teimoori-Toolabi. NOL4 is downregulated and hypermethylated in Papillary Thyroid Carcinoma suggesting its role as a tumor suppressor gene. *Int J Endocrinol Metab*. 2020 Oct 19;18(4):e108510.
22. **Sara Sheikholeslami**, Fereidoun Azizi, Asghar Ghasemi, Abbas Alibakhshi, Hossein Parsa, Setareh Shivaee, Marjan Zarif Yeganeh, Mehdi Hedayati, Ladan Teimoori-Toolabi. The epigenetic modification of SLC5A8 in Papillary Thyroid Carcinoma and its effects on clinic-pathological features. *Iranian Journal of Public Health* (in press).
23. **Sara Sheikholeslami**, Marjan Zarif Yeganeh, Fereidoun Azizi, Asghar Ghasemi, Ladan Teimoori-Toolabi, Mehdi Hedayati. Notable tumor suppressor gene in Thyroid Carcinoma: a Systematic Review. *Iranian Journal of Public Health* (in press).
24. Marjan Zarif-Yeganeh, Dariush.D Farhud, Sima Kheradmand-Kia, Azam Rahimpour, **Sara Sheikholeslami**, Setareh Shivaee, Mehdi Hedayati. Vandetanib and Sorafenib Inhibitory Effects on RET Tyrosine Kinase Downstream Pathway. *Iranian Journal of Public Health* (in press).
25. Marjan Zarif-Yeganeh, Dariush.D Farhud , Sima Kheradmand-Kia, Azam Rahimpour , **Sara Sheikholeslami**, Setareh Shivaee, Mehdi Hedayati. Optimization and Validation of RET Gene Knockout using CRISPR System in Medullary Thyroid Carcinoma Cell lines. *Iranian Journal of Public Health* (in press).

۱. سارا شیخ الاسلامی، مرجان ظریف یگانه، مهدی هدایتی. فراوانی هاپلوتایپ G691S/S904S در بیماران مبتلا به سرطان مدولاری تیروئید. مجله دانشکده پزشکی، دانشگاه علوم پزشکی تهران، آبان ۱۳۹۳، دوره ۷۲، شماره ۸، صفحه های ۵۲۶ تا ۵۳۲.
۲. مرجان ظریف یگانه، سارا شیخ الاسلامی، لاله حقوقی راد، فریدون عزیزی، مهدی هدایتی. جهش های نقطه ای اگزون ۱۰ پروتوآنکوژن RET در بیماران مبتلا به سرطان مدولاری تیروئید. مجله علوم پزشکی کرمان. دوره بیست و دوم، شماره ۳، صفحه های ۲۶۰-۲۴۹، ۱۳۹۴.
۳. مهدی هدایتی، مرجان ظریف یگانه، سارا شیخ الاسلامی، فریدون عزیزی. غربالگری سرطان مدولاری تیروئید با استفاده از نشانگر ژنتیکی پروتوآنکوژن RET. مجله غدد درونریز و متابولیسم ایران. دوره ۱۷، شماره ۲، صفحه های ۱۷۰-۱۵۷ (خرداد-تیر ۱۳۹۴).
۴. مرجان ظریف یگانه، سمیرا کبیری، سارا شیخ الاسلامی، حسنا حسان منش، مهدی هدایتی. جهش های ژرمالین اگزونهای ۱۷ و ۱۸ پروتوآنکوژن RET در بیماران مبتلا به سرطان مدولاری تیروئید در جمعیت ایرانی. مجله دانشکده پزشکی، دانشگاه علوم پزشکی تهران، اسفند ۱۳۹۵، دوره ۷۴، شماره ۱۲، صفحه ۸۵۲ تا ۸۶۰.
۵. حسنا حسان منش، مرجان ظریف یگانه، سارا شیخ الاسلامی، دکتر داریوش فرهود، دکتر مهدی هدایتی. جهش های ژرمالین اگزون ۲ پروتوآنکوژن RET در جمعیت ایرانی مبتلا به کارسینوما مدولاری تیروئید. مجله کومش، جلد ۱۷، شماره ۳ - (بهار ۱۳۹۵): جلد ۱۷. شماره ۳ ۱۳۹۵.
۶. فاطمه نورستی، مرجان ظریف یگانه، سارا شیخ الاسلامی، لاله حقوقی راد، هدی گلاب قدکساز، مهدی هدایتی. بررسی سطح پلاسمایی امننتین در بیماران مبتلا به سرطان مدولاری تیروئید. مجله کومش، جلد ۲۱، شماره ۱، زمستان ۱۳۹۷.
۷. غربالگری سرطان مدولاری تیروئید با استفاده از نشانگر ژنتیکی پروتوآنکوژن RET دکتر مهدی هدایتی، مرجان ظریف یگانه، سارا شیخ الاسلامی، دکتر مریم دانشپور، دکتر فریدون عزیزی
۸. حسنا حسان منش، مرجان ظریف یگانه، سارا شیخ الاسلامی، داریوش دانشور فرهود، مهدی هدایتی. جهش های ژرمالین اگزون ۲ پروتوآنکوژن RET در جمعیت ایرانی مبتلا به کارسینوما مدولاری تیروئید. مجله کومش، جلد ۱۷، شماره ۳ - (بهار ۱۳۹۵): جلد ۱۷. شماره ۳ ۱۳۹۵.

۹. احيائي سميرا، هدايتي مهدي، ظريف يگانه مرجان، شيخ الاسلامي سارا، اميني سيداسداله. مقايسه سطح پلاسمايي هورمون کلسي تونين در افراد مبتلا به سرطان مدولاري تيروييد با و بدون جهش در اگزون ۱۰ و ۱۱ پروتوانکوژن RET. مجله دانشکده پزشکی. دوره ۷۵، شماره ۶ - (شهریور ۱۳۹۶)

INTERNATIONAL CONGRESS & SYMPOSIUM (PUBLISHED ABSTRACTS)

26. Hedayati Mehdi, Zarif Yeganeh Marjan, **Sheikhol Eslam Sara**, Rezghi Barez Shekoufe, Hoghooghi Rad Laleh, Azizi Fereidoun. Predominant RET Germline Mutations in Exons 10, 11, and 16 in Iranian Patients with Hereditary Medullary Thyroid Carcinoma. European Human Genetic Congress. Amesterdam RAI, The Netherlands 28-30 May 2011 (Poster presentation).
27. M. Rafiei, Zarif Yeganeh Marjan, **S. Sheikhol Eslami**, E. Gozalpour, M. Hedayati. Apolipoprotein E polymorphisms statues in Iranian patients with Multiple Sclerosis. European Human Genetic Congress, Nürnberg, Germany, 23-26 June 2012 (Poster presentation).
28. Zarif Yeganeh Marjan, **Sheikholeslami Sara**, Dehbashi Golnoush, Farashi Samaneh, Hoghooghi Rad Laleh, Hedayati Mehdi. Low Prevalence of Germline Mutations in Exons 10 and 16 of the RET proto-oncogene among Iranian Patients with Medullary Thyroid Carcinoma. Yazd, Iran, 16-19 April 2013, International Congress Biochemistry and molecular biology (Poster presentation)
29. **Sheikholeslami Sara**, Zarif Yeganeh Marjan, Dehbashi Golnoush, Farashi Samaneh, Hoghooghi Rad Laleh, Hedayati Mehdi. High Prevalence of haplotype frequency G691S/S904S of the RET proto-oncogene in Iranian Patients with Medullary Thyroid Carcinoma. Yazd, Iran, 16-19 April 2013, International Congress Biochemistry and molecular biology (Oral presentation)
30. Hedayati Mehdi, Zarif Yeganeh Marjan, Guity Kamran, **Sheikholeslami Sara**, Farashi Samaneh, Hoghooghi Rad Laleh. Different Pattern of RET Exons Mutations in Iranian Patients with Hereditary Medullary Thyroid Carcinoma. Yazd, Iran, 16-19 April 2013, International Congress Biochemistry and molecular biology (Poster presentation)
31. Hedayati Mehdi, Farashi Samaneh, Dehbashi Golnoush, **Sheikholeslami Sara**, Zarif Yeganeh Marjan, Hoghooghi Rad Laleh. Genetic Analysis of Exons 5 and 14 of the

- Ret proto-oncogene in Iranian Patients with Medullary Thyroid Carcinoma. Yazd, Iran, 16-19 April 2013, International Congress Biochemistry and molecular biology (Poster presentation)
32. Hedayati Mehdi, Zarif Yeganeh Marjan, **Sheikholeslami Sara**, Farashi Samaneh, G. Dehbashi. RET proto oncogene Mutations in Iranian Patients affected with Medullary Thyroid Cancer. European Human Genetic Congress. June 8-11, Paris, France, 2013 (Poster presentation).
 33. Hedayati Mehdi, Zarif Yeganeh Marjan, **Sheikholeslami Sara**. Pain and Endocrine Evaluation. 4th International congress of interventional pain medicine. Oct 12-14, 2013, Tehran, Iran (Poster Presentation).
 34. **Sheikholeslami Sara**, Zarif Yeganeh Marjan, Hedayati Mehdi. Extended RET proto-oncogene screening in medullary thyroid cancer. European Human Genetic Congress, May 31 – June 3, Milan, Italy, 2014 (Poster presentation).
 35. Zarif Yeganeh Marjan, **Sheikholeslami Sara**, Hedayati Mehdi. RET proto-oncogene main exons' mutations in Iranian patients with medullary thyroid carcinoma. European Human Genetic Congress, May 31 – June 3, Milan, Italy, 2014 (Poster presentation).
 36. Zarif Yeganeh Marjan, **Sara sheikholeslami**, Fereidoun Azizi, Mehdi Hedayati. Hotspot Mutational Spectrum of RET Proto-Oncogene in Hereditary Medullary Thyroid Carcinoma. 1st International & 13th Iranian Genetics Congress. 24-26 May 2014. Tehran. Iran (Poster Presentation).
 37. **Sara sheikholeslami**, Zarif Yeganeh Marjan, Fereidoun Azizi, Mehdi Hedayati. RET proto-oncogene hotspot mutational screening among sporadic medullary thyroid carcinoma. 1st International & 13th Iranian Genetics Congress. 24-26 May 2014. Tehran. Iran (Poster Presentation).
 38. Mehdi Hedayati, Zarif Yeganeh Marjan, **Sara Sheikholeslami**. Mutational spectrum of RET Proto-oncogene in Iranian Patients with Medullary Thyroid Carcinoma. ASHG 2014 Annual Meeting in San Diego, California, October 2014, 18-22. (Poster Presentation)
 39. Mehdi Hedayati, Marjan Zarif Yeganeh, **Sara Sheikholeslami**, Jabar Lotfi. Germline Mutational Spectrum of RET Proto-Oncogene in Iranian Patients with Medullary Thyroid Carcinoma. 10th International Congress of Endocrine Disorders, October 2014, 20-22 (Oral presentation).
 40. Marjan Zarif Yeganeh, Jabar Lotfi, **Sara Sheikholeslami**, Mehdi Hedayati, Aberrant DNA Methylation Profiles as Biomarker for Diagnosis of Thyroid Cancer

- Subtypes. 10th International Congress of Endocrine Disorders, October 2014, 20-22 (Oral presentation).
41. Hoda Golab Ghadaksaz, Mahmood Dehghani Ashkezari, Laleh Hoghooghi Rad, Marjan Zarif Yeganeh, **Sara Sheikholeslami**, Mehdi Hedayati. Association Study of Mutations in Exon 19 of the RET Proto-Oncogene in an Iranian Patients with Medullary Thyroid Carcinoma. 10th International Congress of Endocrine Disorders, October 2014, 20-22 (Poster presentation).
 42. **Sara Sheikholeslami**, Marjan Zarif Yeganeh, Jabar Lotfi, Mehdi Hedayati. The Main Risk Factors for Thyroid Carcinoma. 10th International Congress of Endocrine Disorders, October 2014, 20-22 (Poster presentation).
 43. Jabar Lotfi, **Sara Sheikholeslami**, Marjan Zarif Yeganeh, Behrouz Afarideh, Mehdi Hedayati. Insulin Resistance and Adipokines. 10th International Congress of Endocrine Disorders, October 2014, 20-22 (Poster presentation).
 44. Jabar Lotfi, Marjan Zarif yeganeh, **Sara Sheikholeslami**, Mehdi Hedayati. Lipoic Acid, Is an Anti-Diabetic Vitamin?. 10th International Congress of Endocrine Disorders, October 2014, 20-22 (Poster presentation).
 45. M. Hedayati, M. Zarif Yeganeh, **S. Sheikholeslami**, F. Azizi. Widespread Mutation Detection of RET Proto-oncogene in Medullary Thyroid Carcinoma. European Human Genetics. Conference 2015. June 6-9, 2015 Glasgow, Scotland, United Kingdom (Poster presentation).
 46. Mehdi Hedayati, Marjan Zarif Yeganeh, **Sara Sheikholeslami**, Fereidoun Azizi .Wide screening of RET proto-oncogene in Iranian medullary thyroid carcinoma patients: 13 years study ., 17th European congress of endocrinology, Ireland, Dublin. 16-20 May 2015.
 47. Samira Ehyayi, Mehdi Hedayati, Marjan Zarif Yeganeh, **sara sheikholeslami**, seyed Asadolah Amini. Association between plasma Calcitonin level, mir323-a expression, and RET mutation in Medullary Thyroid Carcinoma. CHINA 17th international congress of endocrinology.
 48. Fatemeh Norasti1, Mehdi Hedayati, Marjan Zarif Yeganeh, **sara Sheikholeslami**, Laleh Hoghooghi Rad, Hoda Golab Ghadaksaz .Plasma level of Omentin in patients with Medullary Thyroid Carcinoma. CHINA 17th international congress of endocrinology.
 49. sepideh jabbari, Mehdi Hedayati, **sara sheikholeslami**, Marjan Zarif Yeganeh, Laleh Hoghooghi Rad, Hoda Golab Ghadaksaz. Association between plasma

- pevels of Vaspin, RBP4 and Medullary Thyroid Carcinoma. CHINA 17th international congress of endocrinology.
50. Razavi Fatemeh, Shady Fathi, **sara sheikholeslami**, Marjan Zarif Yeganeh, Laleh Hoghooghi Rad, Hoda Golab Ghadaksaz, Mehdi Hedayati, Najj Tahereh. Association between plasma levels of Ceruloplasmin and Adiponectin with Medullary Thyroid Carcinoma. CHINA 17th international congress of endocrinology.
 51. Mehdi Hedayati, Marjan Zarif Yeganeh, **Sara Sheikholeslami**, Fereidoun Azizi. RET proto-oncogene germline mutations in Iranian patients with Medullary Thyroid Carcinoma. International Congress on Endocrine Disorders (ICED) November 3 to 5th 2016, Tehran, Iran.
 52. Setareh Shivaee, Marjan Zarif Yeganeh, **Sara Sheikholeslami**, Pazad Parviz, Seyed Mohammad Tavangar, Mehdi Hedayati. RET proto-oncogene somatic mutation in Sporadic Medullary Thyroid Carcinoma patients. 12th International Congress of Endocrine Disorders, November 2018, 14-16 (Oral presentation).
 53. Mehrabi Atefeh, **Sheikholeslami Sara**, Zarif Yeganeh Marjan, Rahmani Samani Mahsa, Rooholah Fatemeh, Hedayati Mehdi. Expression analysis of miR-375, miR-224 and miR-10a in Medullary Thyroid Carcinoma patients. 12th International Congress of Endocrine Disorders, November 2018, 14-16 (Poster presentation).
 54. Rahmani Samani Mahsa, Zarif Yeganeh Marjan, **Sheikholeslami Sara**, Mehrabi Atefeh, Rooholah Fatemeh, Hedayati Mehdi. Expression of miR-127, miR-154 and miR-183 in medullary Thyroid Carcinoma tumors. 12th International Congress of Endocrine Disorders, November 2018, 14-16 (Poster presentation).
 55. **sara sheikholeslami**, marjan zarif yeganeh, setareh shivaee, mehdi hedayati, seyed mohammad tavangar. Expression of mir-129, mir-146, mir-183, and mir-197 in Follicular Thyroid Carcinoma and Adenoma tissues. The 3rd International Congress on Biomedicine. (6-14) November 2019. (Oral presentation).

WORKSHOP, COURSE, & SYMPOSIUM

- Workshop of primary research methodology, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2008.
- Workshop of Advanced research methodology, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2008.
- Workshop of Reverse Transcription-PCR. Biological Engineering Lab, Shahid Beheshti University, Tehran, Iran; 2010.
- Workshop of scientific paper writing, Research Institute of Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2012
- Workshop of Bioinformatics in Genetic studies, Pasteur Institute, Tehran, Iran; 2012.
- Workshop of PROGENY program. Pasteur Institute, Tehran, Iran; 2012.
- Workshop of Real Time PCR. Pasteur Institute, Tehran, Iran; 2013
- Workshop of PCR Primer Design. Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2013.

COMMUNICATION

I was as a leader in 16 research projects and cooperated as a teammate in nine projects.

RESEARCH INTEREST SUBJECTS:

Cancer genetics & Molecular pathway study
Epigenetics
Nutrigenetics and Nutrigenomics
Genome Wide Association Study
Bioinformatics
Population and Statistical genetics

REFERENCES

Fereidoun Azizi, M.D.
Professor of Internal Medicine and Endocrinology
Director, Research Institute for Endocrine Sciences, Shahid Beheshti University of
Medical Sciences
azizi@endocrine.ac.ir

Mehdi Hedayati, Ph.D.
Professor in Biochemistry,
Head, Cellular and Molecular Endocrine Research Center, Research Institute for
Endocrine Sciences
hedayati@endocrine.ac.ir

Ladan Teimoori-Toolabi, M.D. Ph.D.
Assistant Professor
Biotechnology, Cancer biology and Molecular therapies
Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute
of Iran, Tehran, Iran
lteimoori@pasteur.ac.ir